Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06497517 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
A Phase 1 study, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06497517 is a Phase 1 study that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 14 participants.
The verdict
NCT06497517, a Phase 1 study, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.
Interventions
- DRUG GSK5464714- Camlipixant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2024-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06497517
The ClinicalTrials.gov registry entry for NCT06497517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK5464714- Camlipixant is the first listed.
NCT06497517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06497517 about?
NCT06497517 is a clinical study titled "A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants". This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. ...
What is the current status of trial NCT06497517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-07-09. Estimated completion is 2024-08-26.
What interventions are being tested in trial NCT06497517?
The interventions under investigation include: GSK5464714- Camlipixant (DRUG).
Who is sponsoring clinical trial NCT06497517?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.